CA19-9-producing transitional cell carcinoma of the renal pelvis: a case report

Author(s)
TAKI, Tomohiro; HONDA, Nobuaki; YAMADA, Yoshiaki; HIBI, Hatsuki; MITSUI, Kenji; MATSUURA, Osamu; YOSHIKAWA, Kazuhiro

Citation

Issue Date
2001-03

URL
http://hdl.handle.net/2433/114482

Type
Departmental Bulletin Paper

Textversion
publisher

Kyoto University
CA19-9-PRODUCING TRANSITIONAL CELL CARCINOMA OF THE RENAL PELVIS: A CASE REPORT

Tomohiro Taki, Nobuaki Honda, Yoshiaki Yamada, Hatsuki Hibi and Kenji Mitsui
From the Department of Urology, Aichi Medical University
Osamu Matsuura
From the Department of Urology, Komaki Shimin Hospital
Kazuhiro Yoshikawa
From the Department of 2nd Pathology, Aichi Medical University

We report a case of CA19-9-producing transitional cell carcinoma of the renal pelvis. A 59-year-old male patient with left hydronephrosis was referred to us from a local physician. Retrograde pyelogram revealed irregular filling defects involving calices, pelvis and proximal ureter. The serum CA19-9 level was elevated. Under the diagnosis of renal pelvic tumor, we performed radical left nephroureterectomy. The tumor was histologically diagnosed as transitional cell carcinoma. The tumor cells showed positive immunostaining for CA19-9. The serum CA19-9 level was normalized after the operation. To our knowledge, this is the 28th case of a CA19-9-producing tumor in the Japanese literature.

Key words: CA19-9, Renal pelvic tumor, Transitional cell carcinoma

INTRODUCTION

CA19-9 is known as a tumor marker for pancreatic cancer. Recently, there have been sporadic reports of cases of urothelial cancer showing elevated CA19-9 values. Here, we report a case of transitional cell carcinoma in the renal pelvis showing elevation of serum CA19-9 level, and revealed CA19-9 production in the tumor immunohistochemically.

CASE REPORT

A 59-year-old male visited his doctor with a complaint of upper abdominal pain. He had been receiving medication for diabetes for two years. A gastric ulcer, and incidentally, left hydronephrosis were found. Therefore, he was referred to our department. Physical examination revealed no tumor on palpation, and there were no swollen superficial lymph nodes. In the urinary sedimentation, microscopic hematuria was detected. Radiographs revealed a 9×5 mm calcification suspected to be left ureteral lithiasis, and the left kidney was not visualized on intravenous pyelography. Retrograde pyelography revealed filling defects in the renal pelvis (Fig. 1). No abnormal findings were detected in the bladder on the cystoscopy. The cytological examination revealed that the urine aspirated from the left renal pelvis was positive for malignancy.

The white blood cell count and serum creatinin value were slightly elevated. Furthermore, the serum CA19-9 value (cut-off value: <37 U/ml) was also elevated (387.7 U/ml).

The abdominal CT revealed irregular tumor-like shadows in the left renal pelvis (Fig. 2). Chest radiographs and bone scintigrams did not reveal any abnormalities. No abnormalities were detected in the liver, gall bladder or pancreas on the abdominal ultrasonography. We performed left nephroureterectomy and lymph node dissection under the diagnosis of left renal pelvic tumor. The removed
Fig. 2. CT revealed soft-tissue abnormalities of the renal pelvis.

Fig. 3. Histological diagnosis was transitional cell carcinoma.

Fig. 4. Production of CA19-9 was detected by immunostaining.

specimen weighed 550 g, and multiple papillary tumors were found in the renal pelvic tissue macroscopically. Pathological diagnosis was TCC, G3, INFβ, pT1, pN0, pM0, v(+) (Fig. 3). Immunohistochemical staining revealed that CA19-9 presented at the cytoplasm or membrane of the tumor cells (Fig. 4).

From day 20 postoperatively, the patient received two cycles of systemic chemotherapy consisting of cisplatinum (CDDP), adriamycin (ADM) and methotrexate (MTX). The total doses administered were 110,75 and 75 mg for CDDP, ADM and MTX, respectively. No severe adverse effects were observed. The serum CA19-9 value had decreased to 44.0 U/ml on day 14 postoperatively, and to 24.4 U/ml on day 20. Sixteen months have elapsed since the operation, but neither relapse nor elevation of CA19-9 has been observed.

**DISCUSSION**

Koprowski produced hybridomas by fusion of mouse myeloma cells with splenocytes of mice immunized against colorectal carcinoma. The antibodies produced by the hybridomas reacted with CA19-9, a cell surface antigen. CA19-9 is an especially valuable tumor marker for pancreatic and gall-bladder cancers, being detected in 80% of the former and 70% of the latter. Recently, elevated serum CA19-9 values have been reported in patients with transitional cell carcinoma. Segawa et al. reported 20 cases of transitional cell carcinoma showing production of CA19-9. Six cases have been reported since then, and the present case is the 28th case (Table 1). The 28 patients consisted of 20 males and 8 females, and the patients ranged from 43 to 82 years old (mean 61).

A consensus has not been obtained on the

<table>
<thead>
<tr>
<th>No.</th>
<th>Author</th>
<th>Age</th>
<th>Sex</th>
<th>Tumor location</th>
<th>Treatment</th>
<th>Pathology</th>
<th>Prognosis</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>e</td>
<td>66</td>
<td>M</td>
<td>renal pelvis</td>
<td>Chemo</td>
<td>unknown</td>
<td>3 M death</td>
<td>*</td>
</tr>
<tr>
<td>23</td>
<td>e</td>
<td>70</td>
<td>M</td>
<td>renal pelvis</td>
<td>Chemo</td>
<td>unknown</td>
<td>7 M death</td>
<td>*</td>
</tr>
<tr>
<td>28</td>
<td>Our case</td>
<td>59</td>
<td>M</td>
<td>renal pelvis</td>
<td>NUx.</td>
<td>TCC. G3</td>
<td>17 M NED</td>
<td></td>
</tr>
</tbody>
</table>

NUx: Nephroureterectomy, Cx: cystectomy, Chemo: chemotherapy, NED: no evidence of disease, AD: alive with disease.
correlation between the serum CA19-9 value and the pathological features of the tumor. Ishii et al.\(^8\) reported that the detection rate of CA19-9 increased with the increase in degree of tumor infiltration and tumor diameter. On the other hand, Kurokawa et al.\(^9\) reported that the CA19-9 value did not correlate with the tumor size, degree of infiltration or degree of cell differentiation. Further studies on more cases are awaited.

Several studies have recently showed the usefulness of CA19-9 value as a tumor marker. Noto et al.\(^10\) compared the CA19-9 value in the serum and urine of patients with urothelial cancer. They found abnormally high values in the serum in only 27.8\% (10 out of 36 patients), but in the urine in about 67\% (26 out of 36 patients) of the cases. The detection rate and value tended to increase with the degree of tumor differentiation. Especially in G1 and G2 cases, the detection rate was higher than that obtained by urine cytology. They suggested that CA19-9 would be a useful marker for welldifferentiated urothelial carcinoma.

Kurokawa et al.\(^9\) reported that cases not showing postoperative normalization or elevation after postoperative normalization showed recurrence. Segawa et al.\(^2\) reported that the prognosis tended to worsen with the elevation of serum CA19-9 after normalization. In the cases we reviewed, the relapse cases showed elevated serum CA19-9 values (cases 22 and 23 in Table 1). At 12 months postoperatively, relapse has not been observed in the present case. We will continue to follow this case carefully by image analysis and detection of serum CA19-9 as a tumor marker.

**REFERENCES**


(Received on April 12, 2000)
(accepted on September 10, 2000)
CA19-9 産生腎盂移行上皮癌の1例

愛知医科大学泌尿器科学教室（主任：深津英捷教授）

澤 知弘，本多 靖明，山田 芳彰

日比 初紀，三井 健司

松浦 治

愛知医科大学第2病理学教室（主任：佐藤信介教授）

吉川 和宏

CA19-9 産生腎盂移行上皮癌の1例を経験した。59歳の男性が水腎症により当科へ紹介になった。逆行性腎盂造影で左腎盂内に不整陰影欠損を認め，腎盂細胞診が陽性であった。左腎盂腫瘍と診断し左腎盂腫瘍全摘除術を施行，病理診断は移行上皮癌で免疫組織的に腫瘍内に CA19-9 の局在を認めた。術前高値であった血清 CA19-9 が術後漸減，正常化した。術後血清 CA19-9 の上昇ならびに腫瘍の再発を認めていない。CA19-9 産生の腎臓移行上皮癌の本邦報告例として，第28例目であった。

（泌尿器要 47：191-194，2001）